Cargando…
In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on Human endothelial cells
BACKGROUND: LGD1069 (Targretin(®)) is a selective retinoid X receptor (RXR) ligand, which is used in patients for cutaneous T-cell lymphoma. Our published study reported that LGD1069 inhibited tumor-induced angiogenesis in non-small cell lung cancer. In present study, we found that LGD1069 suppresse...
Autores principales: | Fu, Jianjiang, Wang, Wei, Liu, Yu-Hui, Lu, Hong, Luo, Yongming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120806/ https://www.ncbi.nlm.nih.gov/pubmed/21649908 http://dx.doi.org/10.1186/1471-2407-11-227 |
Ejemplares similares
-
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
por: Yen, W-C, et al.
Publicado: (2006) -
Transcriptomic signature of Bexarotene (Rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models
por: Abba, Martin C, et al.
Publicado: (2008) -
Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray
por: SEO, HYE-SOOK, et al.
Publicado: (2015) -
Ligandrol (LGD-4033)-Induced Liver Injury
por: Barbara, Mary, et al.
Publicado: (2020) -
Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
por: Hill, R. P., et al.
Publicado: (1986)